Hydroxychloroquine for prevention of COVID-19

Phase 3

Recruiting

• Conditions: Coronavirus disease

• Registration Number: PACTR202009786901147
• Lead Sponsor: Dr. William Schilling

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-07
• Last Update Posted: 2023-05-29

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

•18 years and above
•Participant is willing and able to give informed consent for participation in the study and agrees with the study and its conduct
•Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals (e.g. not on HAART that includes LPV/r as part of the regimen)
•Not previously diagnosed with COVID-19
•Not currently symptomatic with an acute respiratory infection (ARI)
•Possesses an internet-enabled smartphone (Android or iOS) or computer

Exclusion Criteria

•Hypersensitivity reaction to hydroxychloroquine or 4-aminoquinolines
•Contraindication to taking hydroxychloroquine as prophylaxis, e.g. known epileptic, known creatinine clearance < 10 ml/min
•Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines
•Taking a concomitant medication described in section 8.5 of the master protocol, which cannot be safely stopped known retinal disease
•Inability to be followed up for the trial period
•Known prolonged QT syndrome (ECG will be required for potential participants who report having a heart condition)
•Is enrolled in another clinical trial (however participants will be allowed to participate in observational studies)

Study & Design

• Study Type: Interventional
• Study Design: Not specified